NEWS
MSCI Index Adjustments Take Effect: Aimei vaccines Included in MSCI Global Small Cap Index, Bringing in More Diverse Investors
According to the quarterly index review results announced by MSCI earlier in November, Aimei vaccines (06660) was selected as a component of the MSCI Global Small Cap Index. This adjustment took effect after the market closed yesterday (November 30th).
Some industry insiders believe that Aimei vaccines' inclusion in the MSCI Global Small Cap Index reflects not only the company's outstanding performance in the vaccine field but also is expected to bring more investment opportunities and recognition. This move will not only enhance the company's visibility but also lay a solid foundation for Aimei vaccines' international expansion.
In today's announcement (December 1st), Aimei vaccines stated that its inclusion in the MSCI Global Small Cap Index fully reflects the high degree of recognition of the company's development prospects in the international capital market. It is expected to further expand the company's visibility in the international capital market and attract a more diversified group of investors, thereby increasing the liquidity of the company's shares.
As a leading enterprise in the Chinese vaccine industry, Aimei vaccines has long held an important position in the market. According to brokerage research report data, based on batch issuance and sales revenue in 2021, Aimei vaccines is the largest domestic manufacturer of hepatitis B vaccines and the second-largest manufacturer of human rabies vaccines.
In terms of its product pipeline, Aimei vaccines covers the top ten bestselling vaccines globally and is close to launching products such as the 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), and serum-free Vero cell rabies vaccine in the short term.
UBS recently pointed out that it continues to be optimistic about the Chinese stock market, expecting a 15% upside potential for the MSCI China Index next year. Continuing to be bullish on the Chinese stock market due to its low valuations, light investor positions, accelerated policy support implementation, and improving corporate profitability.
Some industry insiders believe that Aimei vaccines' inclusion in the MSCI Global Small Cap Index reflects not only the company's outstanding performance in the vaccine field but also is expected to bring more investment opportunities and recognition. This move will not only enhance the company's visibility but also lay a solid foundation for Aimei vaccines' international expansion.
In today's announcement (December 1st), Aimei vaccines stated that its inclusion in the MSCI Global Small Cap Index fully reflects the high degree of recognition of the company's development prospects in the international capital market. It is expected to further expand the company's visibility in the international capital market and attract a more diversified group of investors, thereby increasing the liquidity of the company's shares.
As a leading enterprise in the Chinese vaccine industry, Aimei vaccines has long held an important position in the market. According to brokerage research report data, based on batch issuance and sales revenue in 2021, Aimei vaccines is the largest domestic manufacturer of hepatitis B vaccines and the second-largest manufacturer of human rabies vaccines.
In terms of its product pipeline, Aimei vaccines covers the top ten bestselling vaccines globally and is close to launching products such as the 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), and serum-free Vero cell rabies vaccine in the short term.
UBS recently pointed out that it continues to be optimistic about the Chinese stock market, expecting a 15% upside potential for the MSCI China Index next year. Continuing to be bullish on the Chinese stock market due to its low valuations, light investor positions, accelerated policy support implementation, and improving corporate profitability.
